当前位置: 首页 >> 检索结果
4721. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
作者: Marc Ferrante.;Remo Panaccione.;Filip Baert.;Peter Bossuyt.;Jean-Frederic Colombel.;Silvio Danese.;Marla Dubinsky.;Brian G Feagan.;Tadakazu Hisamatsu.;Allen Lim.;James O Lindsay.;Edward V Loftus.;Julián Panés.;Laurent Peyrin-Biroulet.;Zhihua Ran.;David T Rubin.;William J Sandborn.;Stefan Schreiber.;Ezequiel Neimark.;Alexandra Song.;Kristina Kligys.;Yinuo Pang.;Valerie Pivorunas.;Sofie Berg.;W Rachel Duan.;Bidan Huang.;Jasmina Kalabic.;Xiaomei Liao.;Anne Robinson.;Kori Wallace.;Geert D'Haens.
来源: Lancet. 2022年399卷10340期2031-2046页
There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody, was efficacious and well tolerated as induction therapy. Here, we report the efficacy and safety of subcutaneous risankizumab as maintenance therapy.
4722. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
作者: Geert D'Haens.;Remo Panaccione.;Filip Baert.;Peter Bossuyt.;Jean-Frederic Colombel.;Silvio Danese.;Marla Dubinsky.;Brian G Feagan.;Tadakazu Hisamatsu.;Allen Lim.;James O Lindsay.;Edward V Loftus.;Julian Panés.;Laurent Peyrin-Biroulet.;Zhihua Ran.;David T Rubin.;William J Sandborn.;Stefan Schreiber.;Ezequiel Neimark.;Alexandra Song.;Kristina Kligys.;Yinuo Pang.;Valerie Pivorunas.;Sofie Berg.;W Rachel Duan.;Bidan Huang.;Jasmina Kalabic.;Xiaomei Liao.;Anne Robinson.;Kori Wallace.;Marc Ferrante.
来源: Lancet. 2022年399卷10340期2015-2030页
Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease.
4726. Violence against health-care workers in the Philippines.
作者: Michelle Ann B Eala.;Ethan Angelo S Maslog.;Janine Patricia G Robredo.;Raymond Joshua L San Pedro.;Paolo Victor N Medina.;Edelina P De la Paz.;Gideon Lasco.
来源: Lancet. 2022年399卷10340期2012-2013页 4737. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.
Human resources for health (HRH) include a range of occupations that aim to promote or improve human health. The UN Sustainable Development Goals (SDGs) and the WHO Health Workforce 2030 strategy have drawn attention to the importance of HRH for achieving policy priorities such as universal health coverage (UHC). Although previous research has found substantial global disparities in HRH, the absence of comparable cross-national estimates of existing workforces has hindered efforts to quantify workforce requirements to meet health system goals. We aimed to use comparable and standardised data sources to estimate HRH densities globally, and to examine the relationship between a subset of HRH cadres and UHC effective coverage performance.
|